Hearing loss in survivors of childhood head and neck rhabdomyosarcoma: a long‐term follow‐up study

Schoot, Reineke A.; Theunissen, Eleonoor A. R.; Slater, Olga; López-Yurda, Marta; Zuur, Charlotte L.; Gaze, Mark; Chang, Yen-Ching; Mandeville, Henry; Gains, J.; Rajput, Kaukab; Pieters, Bradley R.; Fajardo, Raquel Dávila; Talwar, Rishi; Caron, Huib N.; Balm, Alfons J. M.; Dreschler, Wouter A.; Merks, Johannes H. M.

doi:10.1111/coa.12527

Cited by 13 publications

(18 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment details for this cohort have been described previously; in general, all patients received multidrug chemotherapy and decisions on local therapy were made after two or three courses of chemotherapy. If local therapy was indicated, the patients from the United Kingdom (UK) received external beam radiotherapy and the EKZ‐AMC patients received AMORE (Ablative surgery, MOuld technique after loading brachytherapy, and surgical REconstruction) treatment if feasible and otherwise external beam radiotherapy . AMORE treatment was considered feasible if a macroscopic radical resection and adequate mould placement seemed possible.…”

Section: Methodsmentioning

confidence: 99%

“…If local therapy was indicated, the patients from the United Kingdom (UK) received external beam radiotherapy and the EKZ-AMC patients received AMORE (Ablative surgery, MOuld technique after loading brachytherapy, and surgical REconstruction) treatment if feasible and otherwise external beam radiotherapy. 6,7,[15][16][17] AMORE treatment was considered feasible if a macroscopic radical resection and adequate mould placement seemed possible.…”

Section: Rhabdomyosarcoma Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Psychosocial well‐being of long‐term survivors of pediatric head–neck rhabdomyosarcoma

Vaarwerk

Schoot

Maurice‐Stam

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background Head and neck rhabdomyosarcoma (HNRMS) survivors are at risk to develop adverse events (AEs). The impact of these AEs on psychosocial well‐being is unclear. We aimed to assess psychosocial well‐being of HNRMS survivors and examine whether psychosocial outcomes were associated with burden of therapy. Procedure Sixty‐five HNRMS survivors (median follow‐up: 11.5 years), treated in the Netherlands and the United Kingdom between 1990 and 2010 and alive ≥2 years after treatment visited the outpatient multidisciplinary follow‐up clinic once, in which AEs were scored based on a predefined list according to the Common Terminology Criteria for Adverse Events. Survivors were asked to complete questionnaires on health‐related quality of life (HRQoL; PedsQL and YQOL‐FD), self‐perception (KIDSCREEN), and satisfaction with appearances (SWA). HRQoL and self‐perception scores were compared with reference values, and the correlation between physician‐assessed AEs and psychosocial well‐being was assessed. Results HNRMS survivors showed significantly lower scores on PedsQL school/work domain (P ≤ 0.01, P = 0.02, respectively), YQOL‐FD domains negative self‐image and positive consequences (P ≤ 0.01, P = 0.04, respectively) compared with norm data; scores on negative consequences domain were significantly higher (P = 0.03). Over 50% of survivors negatively rated their appearances on three or more items. Burden of AEs was not associated with generic HRQoL and self‐perception scores, but was associated with disease‐specific QoL (YQOL‐FD). Conclusion In general, HRQoL in HNRMS survivors was comparable to reference groups; however, survivors did report disease‐specific consequences. We therefore recommend including specific questionnaires related to difficulties with facial appearance in a systematic monitoring program to determine the necessity for tailored care.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Rhabdomyosarcoma Treatmentmentioning

confidence: 99%

Psychosocial well‐being of long‐term survivors of pediatric head–neck rhabdomyosarcoma

Vaarwerk

Schoot

Maurice‐Stam

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Radiation involving the ear or auditory nerve is often associated with ototoxicity . Nevertheless, radiation may be required to attain curative treatment for many central nervous system tumors, as well as for malignancies involving structures in the head, such as rhabdomyosarcoma and nasopharyngeal carcinoma . The effects of radiation to the ear appear to be dose‐related, with sensorineural hearing loss generally occurring at doses >30 grays .…”

Section: Introductionmentioning

confidence: 99%

Ototoxicity and cancer therapy

Landier

2016

Cancer

153

129

View full text Add to dashboard Cite

Ototoxicity is a well-established toxicity associated with a subgroup of antineoplastic therapies that includes platinum chemotherapy, radiation or surgery involving the ear and auditory nerve, and supportive care agents such as aminoglycoside antibiotics and loop diuretics. The reported prevalence of ototoxicity in patients who have received potentially ototoxic therapy ranges from 4% to 90% depending on factors such as age of the patient population, agent(s) used, cumulative dose, and administration techniques. The impact of ototoxicity on subsequent health-related and psychosocial outcomes in these patients can be substantial, and the burden of morbidity related to ototoxic agents is particularly high in very young children. Considerable interindividual variability in the prevalence and severity of ototoxicity has been observed among patients receiving similar treatment, suggesting genetic susceptibility as a risk factor. The development and testing of otoprotective agents is ongoing; however, to the author's knowledge, no US Food and Drug Administration-approved otoprotectants are currently available. Prospective monitoring for ototoxicity allows for comparison of auditory outcomes across clinical trials, as well as for early detection, potential alterations in therapy, and auditory intervention and rehabilitation to ameliorate the adverse consequences of hearing loss.

show abstract

“…Patients with head and neck RMS treated with EBRT were found to have higher incidences of hearing loss compared to survivors who had received AMORE based therapy. [12] While our patient's treatment did not follow the AMORE protocol, her treatment did consist of the use of brachytherapy rather than EBRT. EBRT in head and neck RMS patients is also associated with an increased risk to develop any grade 3 event or more than 5 adverse events compared with survivors who received brachytherapy based treatments.…”

Section: Discussionmentioning

confidence: 99%

“…In the head and neck region ERBT can result in hearing loss, facial hypoplasia, developmental delay, xerostomia, dental problems, problems with the pituitary/hypothalamic hormones and second malignancies. [12,13] Brachytherapy is comparatively less damaging because of the localized mechanism of action, which should spare the surrounding tissue.…”

Section: Discussionmentioning

confidence: 99%

Rhabdomyosarcoma of the External Ear Canal Treated with Brachytherapy

Qureshi¹,

Farooki²,

O’Suoji³

2016

WVMJ

View full text Add to dashboard Cite

Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma. RMS of the ear usually involves the middle ear cavity. Treatment usually involves surgery, multi drug chemotherapy regimen, and high dose external beam radiotherapy (EBRT). We present a case of a 17-month-old Caucasian female with an unusual presentation of RMS localized to her external ear canal only, which was initially believed to be an otitis media. Treatment consisted of a regimen involving brachytherapy as the radiation modality rather than EBRT. The goal of brachytherapy use is to decrease morbidity associated with radiation of the head and vital organs in developing children.

show abstract

Hearing loss in survivors of childhood head and neck rhabdomyosarcoma: a long‐term follow‐up study

Cited by 13 publications

References 23 publications

Psychosocial well‐being of long‐term survivors of pediatric head–neck rhabdomyosarcoma

Psychosocial well‐being of long‐term survivors of pediatric head–neck rhabdomyosarcoma

Ototoxicity and cancer therapy

Rhabdomyosarcoma of the External Ear Canal Treated with Brachytherapy

Contact Info

Product

Resources

About